News Headline Summary

MAP Pharmaceuticals (MAPP) investor sues over Allergan acquisition; says offer of USD 958mln undervalues MAP

Reaction details (20:17)

- No immediate reaction in MAPP shares, last trade at USD 24.74.

31 Jan 2013 - 20:15 - - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: